LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Impact of pharmaceutical care for asthma patients on health-related outcomes: An umbrella review.

    Montero Pérez, Olalla / Salazar González, Fernando / Sánchez Gómez, Ernesto / Pérez Guerrero, Concepción

    Pharmacology research & perspectives

    2024  Volume 12, Issue 3, Page(s) e1195

    Abstract: Recent systematic reviews suggest that pharmacists' interventions in asthma patients have a positive impact on health-related outcomes. Nevertheless, the association is not well established, and the role of clinical pharmacists is poorly represented. The ...

    Abstract Recent systematic reviews suggest that pharmacists' interventions in asthma patients have a positive impact on health-related outcomes. Nevertheless, the association is not well established, and the role of clinical pharmacists is poorly represented. The aim of this overview of systematic reviews is to identify published systematic reviews assessing the impact of pharmacists' interventions on health-related outcomes measured in asthma patients. PubMed, Embase, Scopus, and Cochrane Library were searched from inception to December 2022. Systematic reviews of all study designs and settings were included. Methodological quality was assessed using AMSTAR 2. Two investigators performed study selection, quality assessment and data collection independently. Nine systematic reviews met the inclusion criteria. Methodological quality was rated as high in one, low in two, and critically low in six. Reviews included 51 primary studies reporting mainly quality of life, asthma control, lung capacity, and therapeutic adherence. Only four studies were carried out in a hospital setting and only two reviews stated the inclusion of severe asthma patients. The quality of the systematic reviews was generally low, and this was the major limitation of this overview of systematic reviews. However, solid evidence supports that pharmaceutical care improves health-related outcomes in asthma patients.
    MeSH term(s) Asthma/drug therapy ; Humans ; Quality of Life ; Pharmacists ; Medication Adherence/statistics & numerical data ; Pharmaceutical Services ; Professional Role ; Anti-Asthmatic Agents/therapeutic use ; Anti-Asthmatic Agents/administration & dosage ; Systematic Reviews as Topic
    Chemical Substances Anti-Asthmatic Agents
    Language English
    Publishing date 2024-04-22
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2740389-0
    ISSN 2052-1707 ; 2052-1707
    ISSN (online) 2052-1707
    ISSN 2052-1707
    DOI 10.1002/prp2.1195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Pharmaceutical care and asthma: Protocol of an umbrella review of systematic reviews.

    Montero Pérez, Olalla / Salazar González, Fernando / Sánchez Gómez, Ernesto / Pérez Guerrero, Concepción

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

    2023  Volume 47, Issue 4, Page(s) T175–T179

    Abstract: Introduction: Recent systematic reviews and meta-analyses suggest that pharmacists' interventions in asthma patients have a positive impact on health-related outcomes. Nevertheless, the association is not well established and the role of clinical ... ...

    Title translation [Artículo traducido] Atención farmacéutica y asma: protocolo de una revisión de revisiones sistemáticas.
    Abstract Introduction: Recent systematic reviews and meta-analyses suggest that pharmacists' interventions in asthma patients have a positive impact on health-related outcomes. Nevertheless, the association is not well established and the role of clinical pharmacists is poorly represented, as well as severe asthma patients. The aim of this overview of systematic reviews is to identify published systematic reviews assessing the impact of pharmacists' interventions on health-related outcomes measured in asthma patients, as well as to describe key components of the interventions, the outcomes assessed and any associations between pharmacists' interventions and health-related outcomes.
    Methods: PubMed, Embase, Scopus and the Cochrane Library will be searched from inception to December 2022. Systematic reviews of all study designs, severity of asthma and level of care that measured health-related outcomes will be considered. Methodological quality will be assessed using A Measurement Tool to Assess Systematic Reviews 2. Two independent investigators will perform the study selection, quality assessment and data collection, any discrepancy will be solved by a third investigator. Both narrative findings and meta-analysis of primary study data included in the systematic reviews will be synthesized. If data are appropriate for quantitative synthesis, the measures of association will be expressed as the risk ratio and difference in means.
    Discussion: The first results on the establishment of a multidisciplinary network for the management of asthmatic patients have shown the benefits of integrating different levels of care in disease control and morbidity reduction. Further studies showed benefits in hospital admissions, patients' basal oral corticosteroid dose, exacerbations and quality of life of asthma patients. A systematic review is the most appropriate design in order to summarize the literature and identify the evidence of the benefits of interventions performed by clinical pharmacists in asthma patients, especially those with severe uncontrolled asthma, and encourage future studies to stablish the role of clinical pharmacists in asthma units.
    Registration details: Systematic review registration number: CRD42022372100.
    MeSH term(s) Humans ; Asthma/drug therapy ; Hospitalization ; Meta-Analysis as Topic ; Pharmaceutical Services ; Quality of Life ; Systematic Reviews as Topic ; Review Literature as Topic
    Language Spanish
    Publishing date 2023-06-30
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 1122680-8
    ISSN 2171-8695 ; 1130-6343
    ISSN (online) 2171-8695
    ISSN 1130-6343
    DOI 10.1016/j.farma.2023.05.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3450: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review.

    Salazar González, Fernando / Quiñones Palacios, Cristel Andrea / Manzaneque Gordón, Alba / Mazarico Gallego, José María / Díaz, Alba / Molas Ferrer, Gloria

    Anti-cancer drugs

    2023  Volume 35, Issue 3, Page(s) 284–287

    Abstract: Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) pathway have revolutionized cancer immunotherapy by enhancing the immune system's ability to combat cancer cells. However, this innovative approach comes with a distinctive ...

    Abstract Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) pathway have revolutionized cancer immunotherapy by enhancing the immune system's ability to combat cancer cells. However, this innovative approach comes with a distinctive set of challenges, as these therapies can lead to immune-related adverse events (irAEs) due to their mechanism of action. The most common irAEs involve the skin, gastrointestinal tract, liver, endocrine system, and lungs. These events can range from mild skin rashes to severe colitis, pneumonitis, or even autoimmune organ damage. These adverse effects usually appear with an average of 5-15 weeks from the start of treatment depending on the affected organ. This article presents a case report of a delayed related-mediated hepatitis, after 24 months of treatment with pembrolizumab and almost 3 months after its termination, and a review of the scientific literature on cases of delayed immune-related hepatitis caused by anti-PD1. This case highlights the importance of monitoring patients treated with immune checkpoint inhibitors after cessation as a growing number of patients stop treatment due to achieving durable responses.
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors ; Antibodies, Monoclonal, Humanized/adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Skin
    Chemical Substances pembrolizumab (DPT0O3T46P) ; Immune Checkpoint Inhibitors ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-11-13
    Publishing country England
    Document type Review ; Case Reports ; Journal Article
    ZDB-ID 1065301-6
    ISSN 1473-5741 ; 0959-4973
    ISSN (online) 1473-5741
    ISSN 0959-4973
    DOI 10.1097/CAD.0000000000001555
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3125: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Clinical evaluation of antifungal de-escalation in Candida infections: A systematic review and meta-analysis.

    Albanell-Fernández, Marta / Salazar González, Fernando / Montero Pérez, Olalla / Aniyar, Victoria / Carrera Hueso, Francisco-Javier / Soriano, Alex / García-Vidal, Carolina / Puerta-Alcalde, Pedro / Martínez, José Antonio / Vázquez Ferreiro, Pedro

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2024  Volume 143, Page(s) 107020

    Abstract: Objectives: De-escalation (DES) from echinocandins to azoles is recommended by several medical societies in Candida infections. We summarise the evidence of DES on clinical and microbiological cure and 30-day survival and compare it with continuing the ... ...

    Abstract Objectives: De-escalation (DES) from echinocandins to azoles is recommended by several medical societies in Candida infections. We summarise the evidence of DES on clinical and microbiological cure and 30-day survival and compare it with continuing the treatment with echinocandins (non-DES).
    Methods: We searched MEDLINE, Embase, Web of Science and Scopus. Studies describing DES in inpatients and reporting any of the outcomes evaluated were included. Pooled estimates of the tree outcomes were calculated with a fixed or random-effects model. Heterogeneity was explored stratifying by subgroups and via meta-regression. This systematic review is registered with PROSPERO (CRD42023475486).
    Results: Of 1853 records identified, 9 studies were included, totalling 1575 patients. Five studies stepped-down to fluconazole; one to voriconazole and three to any of azoles. The mean day of DES was 5.2 (4.6-6.5) days. The clinical cure OR was 1.29 (95% CI: 0.88-1.88); the microbiological cure 1.62 (95% CI: 0.71-3.71); and 30-day survival 2.17 (95% CI: 1.09-4.32). The 30-day survival data into subgroups showed higher effect on critically ill patients and serious-risk bias studies. Meta-regression did not identify significant effect modifiers.
    Conclusions: DES is a safe strategy; it showed no higher 30-day mortality and a trend towards greater clinical and microbiological cure.
    MeSH term(s) Humans ; Antifungal Agents/therapeutic use ; Candidiasis/drug therapy ; Candidiasis/mortality ; Candidiasis/microbiology ; Fluconazole/therapeutic use ; Candida/drug effects ; Voriconazole/therapeutic use ; Echinocandins/therapeutic use ; Treatment Outcome ; Azoles/therapeutic use ; Azoles/pharmacology
    Chemical Substances Antifungal Agents ; Fluconazole (8VZV102JFY) ; Voriconazole (JFU09I87TR) ; Echinocandins ; Azoles
    Language English
    Publishing date 2024-03-26
    Publishing country Canada
    Document type Systematic Review ; Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2024.107020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4516: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top